


## PCSK9-IN-30

Cat. No.:	HY-161940
Molecular Formula:	C <sub>30</sub> H <sub>33</sub> N <sub>5</sub> O <sub>2</sub>
Molecular Weight:	495.62
Target:	PCSK9
Pathway:	Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

### Description

PCSK9-IN-30 (Compound 3f) is a PCSK9 inhibitor. PCSK9-IN-30 interacts with a cryptic binding groove of PCSK9, inhibiting the binding of PCSK9 to the low-density lipoprotein receptor (LDLR) (IC<sub>50</sub> = 537 nM), restoring the uptake of low-density lipoprotein (LDL) by liver cells, and ultimately reducing plasma cholesterol levels. PCSK9-IN-30 exhibits good bioavailability in mice and can be used for research in the field of cardiovascular diseases<sup>[1]</sup>.

## REFERENCES

- [1]. Bao X, et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. *Signal Transduct Target Ther.* 2024 Jan 8;9(1):13.
- [2]. Evison BJ, et al. A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove. *Bioorg Med Chem.* 2020 Mar 15;28(6):115344.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA